| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Grant revenue | ||||||
3,465 | 1,951 | 1,274 | 1,010 | - | ||
Net product revenue | ||||||
- | - | - | - | 0 | ||
Other revenue | ||||||
- | - | - | - | 0 | ||
Total revenue | ||||||
- | - | - | - | 0 | ||
Operating expenses: | ||||||
Cost of product revenue | ||||||
- | - | 506 | 662 | - | ||
Cost of product revenue | ||||||
- | - | - | - | 0 | ||
Research and development | ||||||
4,018 | 1,287 | 16,989 | 20,378 | 12,749 | ||
General and administrative | ||||||
7,711 | 2,348 | 18,503 | 19,855 | 16,464 | ||
Total operating expenses | ||||||
11,730 | 3,635 | 36,000 | 40,896 | 29,213 | ||
Loss before other income (expense) | ||||||
-8,265 | -1,684 | -34,725 | -39,886 | -29,213 | ||
Change in fair value of warrant liability | ||||||
-1,311 | 0 | - | - | - | ||
Interest income net | ||||||
15 | 14 | - | - | - | ||
Loss from continuing operations | ||||||
-6,938 | -1,669 | - | - | - | ||
Income from discontinued operations | ||||||
1 | 0 | - | - | - | ||
Interest income, net | ||||||
- | - | 291 | 393 | 72 | ||
Net loss | ||||||
-6,936 | -1,669 | -34,433 | -39,493 | -29,141 | ||
Preferred dividends | ||||||
0 | 123 | - | - | - | ||
Loss from continuing operations attributable to common stockholders | ||||||
-6,938 | -1,793 | - | - | - | ||
Loss per common share — basic and diluted | ||||||
Continuing operations (usd per share) | ||||||
-2.12 | -1.16 | - | - | - | ||
Discontinued operations (usd per share) | ||||||
0.00 | 0.00 | - | - | - | ||
Net loss attributable to common stockholders | ||||||
- | - | -34,433 | -39,493 | -29,141 | ||
Net loss per share (usd per share) | ||||||
-2.12 | -1.16 | -1.99 | -2.43 | -2.08 | ||
Weighted-average number of common shares outstanding — basic and diluted | ||||||
3,268 | 1,539 | 17,260 | 16,233 | 14,032 | ||
Net product revenue | ||||||
Total revenue | ||||||
- | - | 1,260 | 989 | - | ||
Other revenue | ||||||
Total revenue | ||||||
- | - | 13 | 20 | - | ||